Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 13Other solid neoplasm 13Gastrointestinal 4Sarcoma 2Gynecologic 2Genitourinary 2Breast 2Head & Neck 1Dermatologic 1

Conditions

Ovarian Neoplasms 96Carcinoma, Ovarian Epithelial 31Fallopian Tube Neoplasms 28Breast Neoplasms 25Carcinoma, Non-Small-Cell Lung 21Melanoma 20Uterine Cervical Neoplasms 16Pancreatic Neoplasms 14Neoplasm Metastasis 13Colorectal Neoplasms 13Stomach Neoplasms 11Triple Negative Breast Neoplasms 10Carcinoma, Hepatocellular 10Sarcoma 9Lung Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Neoplasms 8Anus Neoplasms 8Multiple Myeloma 7Esophageal Neoplasms 7Sarcoma, Synovial 6Neuroblastoma 6Carcinoma, Renal Cell 6Vaginal Neoplasms 5Urinary Bladder Neoplasms 5Testicular Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Penile Neoplasms 5Lymphoma, Non-Hodgkin 5

Interventions

pembrolizumab 2fludarabine 2SS1(dsFv)PE38 2Platinum 2Hyperthermic Intraperitoneal Chemotherapy 2Cyclophosphamide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sodium thiosulfate 1enzalutamide 1entinostat 1X-Rays 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Referral and Consultation 1Polymerase Chain Reaction 1Paclitaxel 1Nivolumab 1Microarray Analysis 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1In Situ Hybridization, Fluorescence 1Immunoenzyme Techniques 1Gene Expression Profiling 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Cyclophosphamide × Gynecologic × Clear all
NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡